Regulatoriskt pressmeddelande

Acarix Changes Publication Date for Q1 2026 Interim Report

Acarix (ticker: Acarix) hereby announces that the company is postponing the release of its interim report for the first quarter of 2026.

The report, which was originally scheduled to be published on May 14, 2026, will now be made public on May 18, 2026, at 08:00 CET.

The reason for the change is that May 14th is a public holiday.

About Acarix

Acarix is a Swedish medical device company that innovates solutions for rapid rule out of coronary artery disease (CAD) at point of care. The CE-approved and FDA DeNovo-cleared Acarix CADScor System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive, and costly diagnostic procedures. The CADScor System has been used on more than 60,000 patients. Acarix recommends CADScor System as a first-line diagnostic aid that uses highly sensitive acoustics and advanced computational processing to analyze coronary blood flow to rule out significant coronary artery disease (CAD), with at least 96% certainty at point of care. Acarix is listed on the Nasdaq First North Premier Growth Market in Stockholm (ticker: ACARIX) and cross-traded on the OTCQB market in the US (ticker: ACIXF). The Company’s Certified Adviser is Tapper Partners AB. For more information, please visit www.acarix.com